Chiesi Group Creates Corporate Venture Capital Fund
Summary
The Chiesi Group, a Parma, Italy-based research-focused international group which researches, develops and commercializes pharmaceutical solutions in the respiratory therapeutics and specialist medicine areas, has created its corporate venture capital fund.The investment focus is on: – Traditional small molecules and biologics, – Advanced therapies – Reformulation technologies and devices – Disease discovery, diagnosis and management.Formed via a collaboration with A. M. Pappas & Associates, which is dedicated to the development of life science companies, products, technologies, and other entrepreneurial opportunities, the firm will operate as an independent investment vehicle while maintaining a strategic connection with the Chiesi Group.It will have offices in Boston, MA, Research Triangle Park, NC and Parma, Italy and will focus on investment opportunities in the US and Europe.Chiesi employs approximately 3,900 people, 480 of which are dedicated to R&D activities having focused centers in Parma (Italy), Paris (France), Rockville (USA), Chippenham (UK) and Denmark with the team of the recently acquired Zymenex.